HC Wainwright Has Positive Outlook for Climb Bio Q2 Earnings

Climb Bio, Inc. (NASDAQ:CLYM) – Research analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for Climb Bio in a report released on Tuesday, May 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.31). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Climb Bio’s Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.93) EPS, Q1 2027 earnings at ($0.21) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.27) EPS and FY2027 earnings at ($0.99) EPS.

Other equities research analysts have also recently issued reports about the company. Truist Financial began coverage on Climb Bio in a research note on Tuesday, March 17th. They issued a “buy” rating and a $17.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research note on Monday, April 20th. Oppenheimer lifted their price objective on Climb Bio from $10.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, April 21st. BTIG Research lifted their price objective on Climb Bio from $8.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Piper Sandler began coverage on Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.30.

Climb Bio Trading Up 2.1%

Shares of NASDAQ CLYM opened at $11.41 on Thursday. Climb Bio has a twelve month low of $1.13 and a twelve month high of $12.48. The stock has a fifty day simple moving average of $8.23 and a 200-day simple moving average of $5.33. The stock has a market capitalization of $653.34 million, a PE ratio of -14.63 and a beta of 0.02.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CLYM. MPM Bioimpact LLC acquired a new position in Climb Bio during the 4th quarter worth $10,686,000. Price T Rowe Associates Inc. MD grew its stake in Climb Bio by 265.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock worth $7,695,000 after purchasing an additional 1,396,722 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in Climb Bio by 972.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after purchasing an additional 1,298,945 shares in the last quarter. Sphera Funds Management LTD. grew its stake in Climb Bio by 114.4% during the 4th quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock worth $3,729,000 after purchasing an additional 497,410 shares in the last quarter. Finally, Kotler Kevin acquired a new position in Climb Bio during the 4th quarter worth $1,600,000. 69.76% of the stock is owned by institutional investors and hedge funds.

Climb Bio News Roundup

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio announced it will present new budoprutug clinical data at the European Hematology Association (EHA) 2026 Congress in June, which could highlight progress in its lead program and support sentiment around the biotech pipeline. Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target on Climb Bio to $20, signaling continued analyst confidence in the stock’s upside. Climb Bio (NASDAQ:CLYM) Given New $20.00 Price Target at HC Wainwright
• Positive Sentiment: HC Wainwright lifted earnings estimates for FY2026, FY2027 and several quarterly periods, suggesting a modestly improving outlook for losses as the company advances its clinical development.
• Neutral Sentiment: The company remains unprofitable, with analyst estimates still calling for losses through 2027, so the near-term story remains focused on pipeline execution rather than earnings power.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.